title: Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
abstract: This retrospective study was designed to assess the accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) in diagnosing recurrence of gastric cancer. Thirty-three patients who had received surgical treatment for gastric cancer with curative intent and who had subsequently undergone FDG-PET for suspected recurrence were retrieved from the PET database. All patients were reviewed with full knowledge of prior conventional diagnostic work-up. Results were compared with a gold standard, consisting of histological confirmation or radiological and clinical follow-up. The gold standard established disease recurrence in 20/33 patients (prevalence 61%). Sensitivity and specificity of FDG-PET for the diagnosis of recurrence were 70% (14/20) and 69% (9/13), respectively. Positive and negative predictive values were 78% (14/18) and 60% (9/15), respectively. Of the six false-negative cases, all had intra-abdominal lesions (three had generalised abdominal metastases, one liver metastasis, one local recurrence and one ovarian metastasis). In the subgroup with previous signet cell differentiation of the primary tumour ( n=13, disease prevalence 62%), sensitivity was 62% (5/8) and specificity, 60% (3/5). Survival analysis for the entire patient group using Kaplan-Meier statistics yielded a longer survival in the PET-negative group (mean+/-SD, 21.9+/-19.0 months) than in the PET-positive group (mean+/-SD, 9.2+/-8.2 months) ( P=0.01). In the patient group with proven recurrence ( n=20), the mean survival for the PET-negative group was 18.5 (+/-12.5) months, as compared with 6.9 (+/-6.5) months for the PET-positive group ( P=0.05). Because of its poor sensitivity and low negative predictive value, FDG-PET is not suited for screening purposes in the follow-up of treated gastric cancer. However, FDG-PET appears to provide important additional information concerning the prognosis of recurrent gastric cancer.
authors.affiliation: Department of Nuclear Medicine, University Hospital Leuven (KU Leuven), Herestraat 49, 3000 Leuven, Belgium.
authors.forename: T
authors.initials: T
authors.lastname: De Potter
authors.forename: P
authors.initials: P
authors.lastname: Flamen
authors.forename: E
authors.initials: E
authors.lastname: Van Cutsem
authors.forename: F
authors.initials: F
authors.lastname: Penninckx
authors.forename: L
authors.initials: L
authors.lastname: Filez
authors.forename: G
authors.initials: G
authors.lastname: Bormans
authors.forename: A
authors.initials: A
authors.lastname: Maes
authors.forename: L
authors.initials: L
authors.lastname: Mortelmans
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D018279:Carcinoma, Signet Ring Cell / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D016208:Databases, Factual; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011859:Radiography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016037:Single-Blind Method; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D014055:Tomography, Emission-Computed / Q000379:methods*; D014915:Whole-Body Counting / Q000379:methods
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18